Pulling SEC filings + quote and writing the call…

Astrana Health, Inc.
Next earnings Aug 5, 2026 · consensus $0.33 EPS, $1.01B rev
Last earnings +2.4% on 2026-05-07
Revenue grew 56.4% YoY; but thin net margin (0.7%).
Weak on both the fundamentals and the price — little to like at the current level.
Sources: SEC EDGAR (CIK 0001083446, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 12:40:32 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Astrana Health, Inc. shows $3.18B in FY2025 revenue (+56.4% YoY), a 0.7% net margin, and 2.9% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $774M | $1.14B | $1.39B | $2.03B | $3.18B |
| Gross profit | — | — | — | — | — |
| Operating income | $98.2M | $104M | $84.6M | $89.3M | $78.5M |
| Net income | $68.9M | $45.2M | $60.7M | $43.1M | $22.5M |
| Diluted EPS | $1.52 | $0.99 | $1.29 | $0.90 | $0.46 |
| Net margin | 8.9% | 3.9% | 4.4% | 2.1% | 0.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1047 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-06-10 | Schmidt David Director | Award | 4.53K | |
| 2026-06-10 | Mazdyasni Matthew Director | Award | 4.53K | |
| 2026-06-10 | Kitayama Mitchell W Director | Award | 4.99K | |
| 2026-06-10 | Dong Linda Director | Award | 4.53K | |
| 2026-06-10 | Dai, Weili Director | Award | 4.53K | |
| 2026-06-10 | Chiang John Director | Award | 4.53K | |
| 2026-05-16 | Basho Chandan COO and CFO | Tax | 8.15K @ $38.26 | $312K |
| 2026-04-14 | Basho Chandan COO and CFO | Tax | 3.87K @ $29.07 | $113K |